Allergy Immunotherapy Market

• The Allergy Immunotherapy Market is expanding rapidly due to rising prevalence of allergic disorders and increasing awareness about long-term allergy management solutions worldwide.

• Growing adoption of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) treatments is improving patient outcomes and adherence rates.

• Rising exposure to environmental pollutants, changing lifestyles, and urbanization are contributing to a surge in allergic conditions such as asthma and rhinitis.

• Technological advancements in personalized allergy diagnostics and biologic-based therapies are enhancing the precision and effectiveness of treatment protocols.

• Europe leads the global market owing to its strong healthcare infrastructure, early adoption of immunotherapy, and robust regulatory support for allergy treatments.

• Manufacturers are investing in novel allergen formulations, combination therapies, and research collaborations to expand their product pipelines and improve patient convenience.

• Increasing government initiatives and public health programs promoting allergy prevention and early intervention are expected to accelerate market growth in the coming years.

• In 2023, Stallergenes Greer, in partnership with Aptar Digital Health, launched the iPUMP connected adherence assistant for sublingual liquid allergen immunotherapy. Real-world data reported in 2025 showed significant improvement in patient adherence, supporting broader adoption and integration of digital health tools within allergen immunotherapy programs. (Source: Aptar)

• Between late 2024 and 2025, DBV Technologies achieved regulatory alignment for an accelerated approval pathway for its Viaskin peanut patch—a patch-based epicutaneous immunotherapy program. The company also secured strategic financing to support late-stage development and prepare for biologics license application (BLA) submission and potential commercial launch.

In this report, the Allergy Immunotherapy Market has been segmented by Treatment Type, Type, Allergy Type, Distribution Channel and Geography.

Allergy Immunotherapy Market, Segmentation by Treatment Type

The Allergy Immunotherapy Market is segmented by treatment type into subcutaneous immunotherapy and sublingual immunotherapy. Each treatment modality offers unique benefits in improving patient outcomes and reducing allergic sensitivity. Increasing awareness and higher treatment success rates are key growth drivers supporting adoption across regions.

Subcutaneous Immunotherapy

This traditional form of immunotherapy involves regular injections that gradually build tolerance to allergens. It remains a standard treatment due to its high efficacy rate, particularly in allergic rhinitis and asthma cases. The segment continues to expand as healthcare providers invest in advanced formulations and improved administration safety.

Sublingual Immunotherapy

This method involves placing drops or tablets under the tongue, offering a non-invasive and convenient alternative to injections. Its popularity is rising due to enhanced patient compliance and reduced clinic visits. The segment is expected to capture a significant share, supported by growing demand in Europe and North America.

Allergy Immunotherapy Market, Segmentation by Type

The market is further segmented by type into tablets and drops, both of which are core delivery mechanisms for sublingual immunotherapy. These options have gained traction due to ease of use and home-based administration advantages, appealing especially to pediatric and elderly patients.

Tablets

Tablets are increasingly preferred owing to standardized dosing and regulatory approvals from agencies like the FDA and EMA. Pharmaceutical companies are developing novel oral formulations targeting multiple allergens, driving market expansion by enhancing patient convenience and adherence.

Drops

Drops offer flexibility in dosing and are commonly prescribed in regions where regulatory pathways for tablet-based products are still evolving. Continuous innovation and product launches are strengthening their market presence, particularly in Asia Pacific and emerging economies.

Allergy Immunotherapy Market, Segmentation by Allergy Type

Based on allergy type, the market is categorized into allergic rhinitis, allergic asthma, and others. The growing global prevalence of respiratory allergies and the demand for long-term curative solutions are fueling expansion across all categories.

Allergic Rhinitis

This segment holds the largest share due to the widespread incidence of seasonal allergies. Immunotherapy provides lasting relief and reduces medication dependency. Increasing urbanization and pollution levels are major market drivers accelerating treatment demand worldwide.

Allergic Asthma

Rising asthma prevalence has led to heightened adoption of immunotherapy treatments aimed at reducing hypersensitivity. Pharmaceutical advancements in allergen extracts are supporting growth. Strategic collaborations between research institutions and biotech firms continue to enhance treatment efficacy.

Others

This category covers less common allergic conditions such as food and insect venom allergies. While smaller in volume, it represents an emerging niche for specialized therapy development, offering promising potential for targeted biologic treatments.

Allergy Immunotherapy Market, Segmentation by Distribution Channel

The distribution landscape for allergy immunotherapy products spans hospital pharmacies, retail pharmacies, and online pharmacies. Increasing patient access and expanding e-commerce infrastructure have diversified distribution strategies, supporting global reach and affordability.

Hospital Pharmacy

Hospital pharmacies dominate due to close patient monitoring and administration of injectable therapies. Institutional purchasing power and integrated healthcare systems ensure a steady flow of immunotherapy products in clinical settings.

Retail Pharmacy

Retail pharmacies play a crucial role in the distribution of tablets and drops, offering accessibility and convenience. Partnerships between pharmaceutical brands and retail networks are driving market penetration across urban and suburban regions.

Online Pharmacy

Online channels are witnessing exponential growth as consumers increasingly prefer digital healthcare solutions. Enhanced logistics and secure prescription management have positioned e-commerce as a vital distribution mode, particularly in developed markets.

Allergy Immunotherapy Market, Segmentation by Geography

In this report, the Allergy Immunotherapy Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

North America

North America leads the market due to advanced healthcare infrastructure and early adoption of immunotherapy. High allergy incidence rates and government support for innovative treatments continue to boost revenue growth in the United States and Canada.

Europe

Europe remains a key region, supported by strong clinical research and favorable reimbursement frameworks. Growing acceptance of sublingual immunotherapy in Germany, France, and the UK underscores technological progress in allergy care.

Asia Pacific

Asia Pacific is the fastest-growing regional market, driven by expanding healthcare access and rising awareness of chronic allergy management. Countries such as Japan, China, and India are witnessing increasing adoption of sublingual therapies.

Middle East & Africa

This region is gradually gaining traction as healthcare investments rise. Ongoing clinical collaborations and allergy prevention initiatives are enhancing the treatment landscape across the Gulf Cooperation Council (GCC) nations and South Africa.

Latin America

Latin America shows growing potential, with Brazil and Mexico emerging as key contributors. Improving diagnostic infrastructure and pharmaceutical distribution networks are driving market penetration across the region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Allergy Immunotherapy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis

Drivers, Restraints and Opportunity Analysis

Key players in Global Allergy Immunotherapy Market include:

• Merck
• Heska
• Biodiagnostic
• ALK
• Allergan plc.
• Sallergenes Greer

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis